lhrh

Luteinizing hormone-releasing hormone (LHRH) is a neuropeptide produced in the hypothalamus that plays a pivotal role in regulating reproduction and has applications in cancer research [1].

Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH (salmon), a gonadotropin-releasing hormone (GnRH) analog, effectively induces ovulation and or spawning in farmed fish [1].

(D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH, an analogue of luteinizing hormone-releasing hormone (LHRH), regulates reproductive processes by stimulating the secretion of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1].

(D-Ser4, D-Ser(tBu)6, Azagly10)-LHRH, an analogue of luteinizing hormone-releasing hormone (LHRH), plays a pivotal role in reproductive regulation by promoting the secretion of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1].

(D-Trp6)-LHRH free acid is a luteinizing hormone-releasing hormone (LHRH) agonist [1].

(D-Tyr5, D-Ser(tBu)6, Azagly10)-LHRH, an analogue of luteinizing hormone-releasing hormone (LHRH), promotes the pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), playing a pivotal role in reproductive control [1].

Antide acetate is an LHRH antagonist and represses LH and FSH release from the pituitary gland.

Surfagon is an effective LHRH agonist.

Teverelix is a water-soluble antagonist of luteinizing hormone-releasing hormone (LHRH).

Goserelin is a gonadotropin-releasing hormone (GnRH LHRH) deceptide-like agent that acts as a GnRH agonist. It is suitable for hormone therapy of prostate cancer, premenopausal and perimenopausal breast cancer, endometriosis.

Goserelin acetate (Fertilan) is a synthetic long-acting agonist of gonadotropin-releasing hormone, used in treatments of cancer.

Ozarelix is a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Mechanistically, LHRH antagonists exert rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones and would therefore be expected to be effective in a variety of hormonally dependent disease states including ovarian cancer, prostate cancer, BPH, infertility, uterine myoma and endometriosis. BPH is a non-cancerous enlargement of the prostate that is caused by testosterone. Unlike LHRH agonists, ozarelix has the potential to reduce testosterone just enough to reduce both prostate size and symptoms without the severe side effects associated with a reduction in testosterone.

Zoptarelin doxorubicin, also known as AEZS-108, is an LHRH agonist. Zoptarelin doxorubicin is a peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Zoptarelin doxorubicin binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation

LH-RH II (chicken), a structural variant of mammalian luteinizing hormone-releasing hormone (LHRH) found in the hypothalamus of the domestic hen, exists as one of two forms of LHRH that enhance gonadotropin release in domestic chickens [1] [2].

[D-Lys6]-LH-RH, a Luteinizing-hormone-releasing hormone (LHRH) analogue, serves as a GnRH receptor agonist [1].

[D-Leu6, Val7]-LH-RH (1-9) Ethyl Amide is an LH-RH peptide analogue.

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH, a luteinizing hormone-releasing hormone (LHRH) analogue, acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist [1].

LH-RH (7-10), a tetrapeptide, constitutes a principal degradation product of luteinizing-hormone releasing hormone (LHRH) through the action of the pituitary and hypothalamus. This compound is synthesized in macrophages, as well as type I-like and type II pneumocytes [3].

LH-RH (4-10), a heptapeptide, represents one of the primary degradation products of luteinising-hormone releasing hormone (LHRH), occurring through the pathways of the pituitary and hypothalamus. It is produced in macrophages and type II pneumocytes [1].

Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is a luteinizing hormone-releasing hormone (LHRH) analogue with antineoplastic properties, characterized by the peptide sequence KFAKFAKKFAKFAKKFAKQHWSYGLRPG. It is effective in inhibiting breast, ovarian, and prostate cancer xenografts in mouse models [1] [2].

[D-Phe2,6, Pro3]-LH-RH is a potent antagonist of luteinizing hormone-releasing hormone (LHRH).

Luteinizing Hormone Releasing Hormone (LH-RH), synthesized in the hypothalamus, is a pituitary hormone that plays a crucial role in controlling reproductive function.

LH-RH, salmon acetate(86073-88-3 free base) (Luteinizing Hormone Releasing Hormone (LH-RH), salmon acetate) is a pituitary Hormone synthesized in the hypothalamus and plays a crucial role in the control of reproductive function.

GnRH-I is a small 10 amino acid long peptide (decapeptide) from the hypothalamus,It is also known as luteinizing hormone releasing hormone (LHRH), is a key molecule in the regulation of reproduction in vertebrates. GnRH, a decapeptide, is produced by neur